10x Genomics
305 hedge funds and large institutions have $9.38B invested in 10x Genomics in 2020 Q4 according to their latest regulatory filings, with 124 funds opening new positions, 105 increasing their positions, 59 reducing their positions, and 38 closing their positions.
226% more first-time investments, than exits
New positions opened: 124 | Existing positions closed: 38
212% more call options, than puts
Call options by funds: $27.5M | Put options by funds: $8.82M
78% more repeat investments, than reductions
Existing positions increased: 105 | Existing positions reduced: 59
39% more funds holding
Funds holding: 219 → 305 (+86)
10% more capital invested
Capital invested by funds: $8.54B → $9.38B (+$843M)
8.12% less ownership
Funds ownership: 90.76% → 82.64% (-8.1%)
9% less funds holding in top 10
Funds holding in top 10: 11 → 10 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$272M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$215M |
| 3 |
William Blair Investment Management
Chicago,
Illinois
|
+$186M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$88M |
| 5 |
State Street
Boston,
Massachusetts
|
+$73.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VMV
Venrock Management VI
Palo Alto,
California
|
-$914M |
| 2 |
Morgan Stanley
New York
|
-$435M |
| 3 |
Fidelity International
Hamilton,
Bermuda
|
-$322M |
| 4 |
FCMI
Foresite Capital Management I
Larkspur,
California
|
-$218M |
| 5 |
Capital World Investors
Los Angeles,
California
|
-$159M |
TXG Hedge Fund Activity: Q4 2020 in Review
305 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in 10x Genomics (TXG) for Q4 2020, worth a combined $9.38B — up 9.9% from $8.54B a quarter earlier.
Buyers outnumbered sellers: 124 funds opened new TXG positions and 38 closed out — a net gain of 86 holders — while 105 added to existing stakes and 59 trimmed.
The largest buyer was BlackRock, adding an estimated $272M. The largest seller was Venrock Management VI, cutting an estimated $914M.
- 305 institutional investors held 10x Genomics (TXG) as of Q4 2020, up from 219 in Q3 2020.
- Funds reported $9.38B of 10x Genomics stock for Q4 2020, up 9.9% quarter-over-quarter.
- 124 funds opened new 10x Genomics positions in Q4 2020 and 38 closed out, a net change of +86 holders.
- The largest 10x Genomics buyer in Q4 2020 was BlackRock, an estimated $272M added.
- The largest 10x Genomics seller in Q4 2020 was Venrock Management VI, an estimated $914M sold.
Based on aggregated 13F filings for Q4 2020.